Press Releases Year None202020192018201720162015201420132012 July 6, 2020 Lineage Cell Therapeutics Announces Extension of OpRegen® Development Grant From Israel Innovation Authority June 25, 2020 Lineage Cell Therapeutics Provides Update on OPC1 Cell Therapy Program for Spinal Cord Injury June 24, 2020 Lineage Cell Therapeutics to Present OpRegen® Data at International Society for Stem Cell Research (ISSCR) 2020 Virtual Annual Meeting June 18, 2020 Lineage Cell Therapeutics Reinitiates Patient Enrollment in Clinical Study of OpRegen® for the Treatment of Dry AMD With Geographic Atrophy June 17, 2020 Lineage Cell Therapeutics to Present Tomorrow at 2020 Raymond James Human Health Innovation Conference June 11, 2020 Lineage Cell Therapeutics to Present at 2020 Raymond James Human Health Innovation Conference on June 18, 2020 June 8, 2020 Lineage Cell Therapeutics to Host Therapeutic Expert Call Today to Discuss the First Known Reported Finding of Retinal Tissue Regeneration with OpRegen® in Dry AMD with Geographic Atrophy June 1, 2020 Lineage Cell Therapeutics Reports Regeneration of Retinal Tissue in Patient Treated With OpRegen RPE Cells for Dry AMD With Geographic Atrophy May 19, 2020 Lineage Cell Therapeutics to Participate in Maxim Group and M-Vest COVID-19 Virtual Conference Series on May 27, 2020 May 18, 2020 Lineage Cell Therapeutics to Present at 2020 Solebury Trout Virtual Investor Conference on May 26, 2020 May 7, 2020 Lineage Cell Therapeutics Reports First Quarter 2020 Financial Results and Provides Business Update May 7, 2020 Lineage Cell Therapeutics Announces Early Exercise of Option with Cancer Research UK for Immuno-Oncology Cell Therapy Program May 6, 2020 Lineage Cell Therapeutics Reports New Data With OpRegen for the Treatment of Dry AMD With Geographic Atrophy May 5, 2020 Lineage Cell Therapeutics to Apply Allogeneic Dendritic Cell Therapy Program to COVID-19 Vaccine Development April 29, 2020 Lineage Cell Therapeutics to Report First Quarter 2020 Financial Results and Provide Business Update on May 7, 2020 April 24, 2020 Lineage Cell Therapeutics Conducts Sale of Shares in OncoCyte Corporation April 16, 2020 Lineage Cell Therapeutics CEO Letter March 12, 2020 Lineage Cell Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Business Update March 5, 2020 Lineage Cell Therapeutics to Report Fourth Quarter and Full Year 2019 Financial Results and Provide Business Update on March 12, 2020 February 20, 2020 Lineage Cell Therapeutics to Present at Biocom’s 10th Annual Global Life Sciences Partnering Conference February 18, 2020 Lineage Cell Therapeutics to Present New Data From OpRegen® and Vision Restoration Programs at the Association for Research in Vision and Ophthalmology Annual Meeting (ARVO 2020) February 10, 2020 Lineage Cell Therapeutics to Present at NobleCon16 - Noble Capital Markets' Sixteenth Annual Investor Conference February 6, 2020 Lineage Provides Positive Update on Phase I/IIa Clinical Study of OpRegen® for the Treatment of Dry Age-Related Macular Degeneration January 2, 2020 Lineage Cell Therapeutics Conducts Sale of Shares in OncoCyte Corporation
July 6, 2020 Lineage Cell Therapeutics Announces Extension of OpRegen® Development Grant From Israel Innovation Authority
June 25, 2020 Lineage Cell Therapeutics Provides Update on OPC1 Cell Therapy Program for Spinal Cord Injury
June 24, 2020 Lineage Cell Therapeutics to Present OpRegen® Data at International Society for Stem Cell Research (ISSCR) 2020 Virtual Annual Meeting
June 18, 2020 Lineage Cell Therapeutics Reinitiates Patient Enrollment in Clinical Study of OpRegen® for the Treatment of Dry AMD With Geographic Atrophy
June 17, 2020 Lineage Cell Therapeutics to Present Tomorrow at 2020 Raymond James Human Health Innovation Conference
June 11, 2020 Lineage Cell Therapeutics to Present at 2020 Raymond James Human Health Innovation Conference on June 18, 2020
June 8, 2020 Lineage Cell Therapeutics to Host Therapeutic Expert Call Today to Discuss the First Known Reported Finding of Retinal Tissue Regeneration with OpRegen® in Dry AMD with Geographic Atrophy
June 1, 2020 Lineage Cell Therapeutics Reports Regeneration of Retinal Tissue in Patient Treated With OpRegen RPE Cells for Dry AMD With Geographic Atrophy
May 19, 2020 Lineage Cell Therapeutics to Participate in Maxim Group and M-Vest COVID-19 Virtual Conference Series on May 27, 2020
May 18, 2020 Lineage Cell Therapeutics to Present at 2020 Solebury Trout Virtual Investor Conference on May 26, 2020
May 7, 2020 Lineage Cell Therapeutics Reports First Quarter 2020 Financial Results and Provides Business Update
May 7, 2020 Lineage Cell Therapeutics Announces Early Exercise of Option with Cancer Research UK for Immuno-Oncology Cell Therapy Program
May 6, 2020 Lineage Cell Therapeutics Reports New Data With OpRegen for the Treatment of Dry AMD With Geographic Atrophy
May 5, 2020 Lineage Cell Therapeutics to Apply Allogeneic Dendritic Cell Therapy Program to COVID-19 Vaccine Development
April 29, 2020 Lineage Cell Therapeutics to Report First Quarter 2020 Financial Results and Provide Business Update on May 7, 2020
March 12, 2020 Lineage Cell Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Business Update
March 5, 2020 Lineage Cell Therapeutics to Report Fourth Quarter and Full Year 2019 Financial Results and Provide Business Update on March 12, 2020
February 20, 2020 Lineage Cell Therapeutics to Present at Biocom’s 10th Annual Global Life Sciences Partnering Conference
February 18, 2020 Lineage Cell Therapeutics to Present New Data From OpRegen® and Vision Restoration Programs at the Association for Research in Vision and Ophthalmology Annual Meeting (ARVO 2020)
February 10, 2020 Lineage Cell Therapeutics to Present at NobleCon16 - Noble Capital Markets' Sixteenth Annual Investor Conference
February 6, 2020 Lineage Provides Positive Update on Phase I/IIa Clinical Study of OpRegen® for the Treatment of Dry Age-Related Macular Degeneration
